因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INCY 因塞特医疗

交易中 11-22 13:14:59 EST

71.68

+1.29

+1.83%

最高72.00	最低70.33	成交量45.76万
今开70.43	昨收70.39	日振幅2.37%
总市值138.09亿	流通市值115.04亿	总股本1.93亿
成交额3,266万	换手率0.29%	流通股本1.60亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"因塞特医疗","latestPrice":71.68,"timestamp":1732299287616,"preClose":70.39,"halted":0,"volume":457643,"delay":0,"floatShares":160497018,"shares":192650249,"eps":0.14839,"marketStatus":"交易中","marketStatusCode":2,"change":1.29,"latestTime":"11-22 13:14:59 EST","open":70.43,"high":72,"low":70.33,"amount":32657903.310870003,"amplitude":0.023725,"askPrice":71.69,"askSize":12,"bidPrice":71.63,"bidSize":247,"shortable":3,"etf":0,"ttmEps":0.14839,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732309200000},"adr":0,"adjPreClose":70.39,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":70.53,"preClose":70.39,"latestTime":"09:29 EST","volume":485,"amount":34266.268500000006,"timestamp":1732285799999},"postHourTrading":{"tag":"盘后","latestPrice":70.39,"preClose":70.39,"latestTime":"19:23 EST","volume":38252,"amount":2692611.43,"timestamp":1732235027971},"volumeRatio":0.188619,"impliedVol":0.6027,"impliedVolPercentile":0.9921},"requestUrl":"/m/hq/s/INCY","defaultTab":"news","newsList":[{"id":"2484692598","title":"因塞特股价重挫12.29% 市值跌15.98亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484692598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484692598?lang=zh_cn&edition=full","pubTime":"2024-11-19 22:31","pubTimestamp":1732026666,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日22时31分，因塞特股票出现异动，股价急速跳水12.29%。截至发稿，该股报67.51美元/股，成交量15.3454万股，换手率0.08%，振幅1.81%。最近的财报数据显示，该股实现营业收入11.38亿美元，净利润1.06亿美元，每股收益0.55美元，毛利10.35亿美元，市盈率750.11倍。因塞特股票所在的生物技术行业中，整体跌幅为0.46%。因塞特公司简介：Incyte专注于小分子药物的发现和开发。该公司的第一个皮肤科产品 Opzelura 于 2021 年被批准用于特应性皮炎，2022 年被批准用于白斑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922310695be4a6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922310695be4a6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4550","BK4532","INCY","BK4139","BK4588"],"gpt_icon":0},{"id":"2484945400","title":"BUZZ-Incyte 暂停慢性皮肤病试验后暴跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2484945400","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484945400?lang=zh_cn&edition=full","pubTime":"2024-11-19 20:48","pubTimestamp":1732020514,"startTime":"0","endTime":"0","summary":"    11月19日 - ** 制药商Incyte公司  股价盘前下跌11.7%至68美元** 周一，Incyte公司表示，出于安全考虑，它暂停了一项治疗自发性荨麻疹慢性皮肤病的实验性药物中期试验的注册 。** INCY还表示，另一种治疗严重瘙痒症的实验性药物的中期试验数据不支持进一步开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4139","BK4588","BK4585","BK4550","BK4532"],"gpt_icon":0},{"id":"2484982133","title":"BUZZ-Incyte 暂停皮肤病治疗早期研究后业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2484982133","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484982133?lang=zh_cn&edition=full","pubTime":"2024-11-19 06:00","pubTimestamp":1731967242,"startTime":"0","endTime":"0","summary":"BUZZ-Incyte 暂停皮肤病治疗早期研究后业绩下滑11月18日 -  ** 制药商Incyte InCY的股价在盘后交易中下跌约6%，至72.48美元 ** 公司暂停正在进行的慢性自发性荨麻疹 治疗的早期阶段研究的注册工作 ** 称其胆汁淤积性瘙痒症治疗的 2 期研究数据不值得进一步开发 ** CSU 是一种会引起荨麻疹的皮肤病，而胆汁淤积性瘙痒症会引起严重的瘙痒感 ** 截至去年收盘，股价上涨约 21(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nL4T3MP1IR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4550","BK4585","BK4532","INCY","BK4588"],"gpt_icon":0},{"id":"2483327055","title":"美国 FDA 批准 Syndax 的血癌药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2483327055","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483327055?lang=zh_cn&edition=full","pubTime":"2024-11-16 07:24","pubTimestamp":1731713063,"startTime":"0","endTime":"0","summary":"路透11月15日 - 美国食品和药物管理局周五批准了Syndax Pharmaceuticals公司SNDX.O用于治疗成人和儿童血癌患者的药物，该公司股价在盘后交易中上涨了3%。该药物的批准是基于一项有104名患者参加的早中期试验，结果显示21%的患者病情完全缓解，特定血细胞水平部分恢复。Syndax公司预计，110毫克和160毫克的Revuforj片剂将于本月在美国上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nL4T3MM1M7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDX","INCY","BK4139","BK4588","BK4585","BK4550","BK4532"],"gpt_icon":0},{"id":"2481598531","title":"因塞特盘中异动 急速上涨5.16%报81.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481598531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481598531?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:38","pubTimestamp":1730903913,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时38分，因塞特股票出现波动，股价大幅拉升5.16%。截至发稿，该股报81.27美元/股，成交量47.6883万股，换手率0.25%，振幅3.60%。最近的财报数据显示，该股实现营业收入11.38亿美元，净利润1.06亿美元，每股收益0.55美元，毛利10.35亿美元，市盈率895.56倍。因塞特股票所在的生物技术行业中，整体跌幅为0.23%。因塞特公司简介：Incyte专注于小分子药物的发现和开发。该公司的第一个皮肤科产品 Opzelura 于 2021 年被批准用于特应性皮炎，2022 年被批准用于白斑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223833971a4c74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223833971a4c74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY","BK4139","BK4550","BK4588","BK4532","BK4585"],"gpt_icon":0},{"id":"2480487589","title":"因塞特2024财年第三财季实现净利润1.06亿美元，同比减少38.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480487589","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480487589?lang=zh_cn&edition=full","pubTime":"2024-11-03 00:00","pubTimestamp":1730563240,"startTime":"0","endTime":"0","summary":"11月3日，因塞特公布财报，公告显示公司2024财年第三财季净利润为1.06亿美元，同比减少38.01%；其中营业收入为11.38亿美元，同比增加23.83%，每股基本收益为0.55美元。从资产负债表来看，因塞特总负债18.41亿美元，其中短期债务8.28百万美元，资产负债比为2.73，流动比率为1.88。机构评级：截至2024年11月3日，当前有20家机构对因塞特目标价做出预测，其中目标均价为77.45美元，其中最低目标价为52.00美元，最高目标价为97.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000051a20f7aba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000051a20f7aba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"2479003281","title":"BUZZ-Incyte公司因销量最高的药物Jakafi的2024年销售预期提升而攀升","url":"https://stock-news.laohu8.com/highlight/detail?id=2479003281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479003281?lang=zh_cn&edition=full","pubTime":"2024-10-29 22:48","pubTimestamp":1730213296,"startTime":"0","endTime":"0","summary":"    10月29日 - ** 制药商Incyte   股价上涨约8%至70.95美元，创5月份以来新高** Incyte预计，  2024年其血癌药物Jakafi的销售额将在27.4亿美元至27.7亿美元之间，而之前的预测为27.1亿美元至27.5亿美元。** 公司第三季度营收为 11.4 亿美元，高于分析师平均预期的 10.7 亿美元 - LSEG** Cantor Fitzgerald 的分析师说：\"我们认为 INCY 的基础业务在 2029 年初之前都是稳定到适度增长的现金奶牛，预计届时 Jakafi 将成为仿制药。** 包括本交易日的走势在内，该股今年累计上涨 13","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4550","BK4532","BK4139","BK4585","INCY"],"gpt_icon":0},{"id":"1154069484","title":"异动解读 | 因塞特医疗公司业绩佳绩 股价盘中大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154069484","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154069484?lang=zh_cn&edition=full","pubTime":"2024-10-29 21:39","pubTimestamp":1730209160,"startTime":"0","endTime":"0","summary":"因塞特医疗公司10月29日股价盘中大涨5.01%,引发市场关注。公司当日发布的第三季度业绩显示营收和利润均超出华尔街预期,这是其股价上涨的主要推手。财报数据显示,第三季度因塞特医疗公司最畅销的Jakafi药物销售额同比增长16%,达到7.41亿美元。同时,公司治疗白癜风和特应性皮炎的新药物Opzelura销售也录得52%的强劲增长。受两大产品表现强劲拉动,公司第三季度营收为11.4亿美元,超出分析师预期。公司还上调了Jakafi2024年全年销售预期至27.4-27.7亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 因塞特医疗公司业绩佳绩 股价盘中大涨5%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INCY"],"gpt_icon":0},{"id":"2479880512","title":"因塞特盘中异动 早盘急速上涨5.24%报69.13美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479880512","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479880512?lang=zh_cn&edition=full","pubTime":"2024-10-29 21:33","pubTimestamp":1730208815,"startTime":"0","endTime":"0","summary":"北京时间2024年10月29日21时33分，因塞特股票出现波动，股价快速上涨5.24%。截至发稿，该股报69.13美元/股，成交量8.0303万股，换手率0.04%，振幅2.79%。因塞特股票所在的生物技术行业中，整体跌幅为0.18%。因塞特公司简介：Incyte专注于小分子药物的发现和开发。该公司的第一个皮肤科产品 Opzelura 于 2021 年被批准用于特应性皮炎，2022 年被批准用于白斑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029213336971a2eb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029213336971a2eb6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4585","BK4532","BK4588","INCY","BK4550"],"gpt_icon":0},{"id":"2479005407","title":"Incyte上调畅销药物Jakafi的2024年销售额预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2479005407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479005407?lang=zh_cn&edition=full","pubTime":"2024-10-29 21:19","pubTimestamp":1730207962,"startTime":"0","endTime":"0","summary":"    路透10月29日 - Incyte  周二公布的第三季度营收超出华尔街预期，并上调了其畅销药物的年销售额预期，因为患者对该药物的接受程度依然强劲。公司预计随着时间的推移，PV将成为Jakafi的最大贡献者。Incyte 预计，2024 年 Jakafi 的销售额将在 27.4 亿美元到 27.7 亿美元之间，而之前的预测为 27.1 亿美元到 27.5 亿美元。第三季度，Jakafi 的销售额增长了 16%，达到 7.41 亿美元，超过了 7.252 亿美元的预期。经调整后，Incyte 在截至 9 月 30 日的这一季度每股收益为 1.07 美元，符合预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","INCY","BK4550","BK4588","BK4139"],"gpt_icon":0},{"id":"2478806699","title":"Incyte Corp   预计每股收益1.11美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2478806699","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478806699?lang=zh_cn&edition=full","pubTime":"2024-10-25 21:16","pubTimestamp":1729862161,"startTime":"0","endTime":"0","summary":"   * Incyte公司   预计将在10月29日公布截至2024年9月30日的季度收入报告。* 根据LSEG的数据，18位分析师的平均预期显示，这家总部位于美国特拉华州威尔明顿市的公司的营收将从去年同期的9.1903亿美元增至10.76亿美元，增幅为17.1%。   * LSEG 分析师对 Incyte Corp 的平均预期为每股收益 1.11 美元。* 华尔街对 Incyte Corp 的 12 个月目标价中位数为 74.00 美元，高于其上次收盘价 65.24 美元。10月25日 - 上一季度业绩。除非另有说明，所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Incyte Corp   预计每股收益1.11美元 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"2477932700","title":"美国研究综述-BXP、Medpace Holdings、星巴克","url":"https://stock-news.laohu8.com/highlight/detail?id=2477932700","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477932700?lang=zh_cn&edition=full","pubTime":"2024-10-23 14:34","pubTimestamp":1729665251,"startTime":"0","endTime":"0","summary":"    路透10月23日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 BXP、Medpace Holdings 和星巴克。* 丹纳赫公司  ：TD Cowen将目标价从310美元上调至315美元              * Medpace Holdings Inc   ：杰富瑞将目标价从345美元下调至305美元              * 星巴克   ：Stifel将目标价从110美元下调至105美元              * Wintrust Financial Corp   ：Truist Securities将目标价从123美元上调至127美元  以下是路透周三报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZION","GM","TW","BK4187","LU0320765489.SGD","SLB","RHI","SHW","CADE","LU0114720955.EUR","BK4112","LU0162691827.USD","PATK","LU2404859667.USD","SBUX","LU0353189763.USD","MDGL","ENVA","WTFC","PII","VNO","IE000M9KFDE8.USD","MEDP","CSGP","EWBC","PM","LU0054578231.USD","IBTX","BXP","LU1923621640.USD","FI","LU1551013342.USD","HSY","PHM","GPC","PATH","BANC","BK4212","LU0823411888.USD","BK4539","MDLZ","PEBO","BK4166","INCY","SG9999001176.USD","LU1551013425.SGD","IQV","DHR"],"gpt_icon":1},{"id":"2477000327","title":"美国研究综述-BXP、Medpace Holdings、星巴克","url":"https://stock-news.laohu8.com/highlight/detail?id=2477000327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477000327?lang=zh_cn&edition=full","pubTime":"2024-10-23 14:34","pubTimestamp":1729665251,"startTime":"0","endTime":"0","summary":"    路透10月23日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括 BXP、Medpace Holdings 和星巴克。* 丹纳赫公司  ：TD Cowen将目标价从310美元上调至315美元              * Medpace Holdings Inc   ：杰富瑞将目标价从345美元下调至305美元              * 星巴克   ：Stifel将目标价从110美元下调至105美元              * Wintrust Financial Corp   ：Truist Securities将目标价从123美元上调至127美元  以下是路透周三报导的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDLZ","BK4187","BK4112","CADE","FI","PATH","LU0320765489.SGD","GPC","SLB","TW","PII","GM","HSY","IE000M9KFDE8.USD","LU0054578231.USD","VNO","BANC","DHR","ZION","LU1551013425.SGD","PEBO","LU1551013342.USD","EWBC","WTFC","IBTX","PM","ENVA","LU0353189763.USD","PHM","LU0823411888.USD","PATK","BK4539","RHI","INCY","LU2404859667.USD","LU0114720955.EUR","MDGL","SHW","CSGP","LU1923621640.USD","LU0162691827.USD","BK4166","BXP","SBUX","BK4212","IQV","MEDP","SG9999001176.USD"],"gpt_icon":1},{"id":"2468430787","title":"BUZZ-Truist下调Incyte评级至 \"持有\"，因近期前景存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=2468430787","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468430787?lang=zh_cn&edition=full","pubTime":"2024-09-18 19:27","pubTimestamp":1726658841,"startTime":"0","endTime":"0","summary":"    9月18日 - ** Truist Securities将Incyte公司  的评级从 \"买入 \"下调至 \"持有\"，将目标价从83美元下调至74美元。** 券商质疑该公司在免疫学和肿瘤学领域的产品线能否抵消因失去最大畅销血液病药物Jakafi的 \"独家 \"标签而造成的收入损失。** 券商称 \"在我们看到多个项目的数据支持大片产品弥补 Jakafi 损失的潜力之前，我们仍持观望态度\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"2459281046","title":"Incyte公司血癌药物后期试验取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2459281046","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459281046?lang=zh_cn&edition=full","pubTime":"2024-08-16 07:03","pubTimestamp":1723763025,"startTime":"0","endTime":"0","summary":"    路透8月15日 - Incyte公司  周四说，它的药物在一项晚期试验中达到了主要目标，该试验对一种血癌患者进行了评估。该公司说，它的药物Monjuvi与百时美施贵宝  的药物Revlimid和百健  的Rituxan联合使用，与单独使用Rituxan和Revlimid相比，滤泡性淋巴瘤患者的无进展生存期。Monjuvi 与Revlimid联合用药已被批准用于治疗弥漫性大B细胞淋巴瘤，这也是非霍奇金淋巴瘤的一种亚型。根据这项试验的结果，Incyte 预计将在今年年底前向 FDA 提交补充上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","IE00BFTCPJ56.SGD","BMY","LU2125154778.USD","IE00BKVL7J92.USD","LU0109394709.USD","BK4578","LU0985481810.HKD","IE00BZ1G4Q59.USD","GILD","BIIB","LU2133065610.SGD","LU1430594728.SGD","BK4566","IE0009355771.USD","LU1670710661.SGD","LU0889565916.HKD","LU0225284248.USD","LU1839511570.USD","BK4568","LU1718418525.SGD","IE00B2B36J28.USD","LU0114720955.EUR","LU2125154935.USD","LU1670711040.USD","FL","BK4588","LU0321505439.SGD","IE0002141913.USD","BK4139","LU2242646821.SGD","LU0456855351.SGD","LU1670711123.USD","LU0234570918.USD","LU2360032135.SGD","LU2242652126.USD","LU1670710588.SGD","LU1032466523.USD","LU1074936037.SGD","IE00BSNM7G36.USD","LU0306807586.USD","LU1066053197.SGD","LU1291159041.SGD","BK4550","BK4585","LU2087621335.USD","INCY","IE00B19Z9Z06.USD","BK4581","LU0306806265.USD"],"gpt_icon":0},{"id":"2459403760","title":"BUZZ-美国食品和药物管理局批准 Syndax 治疗慢性移植物抗宿主病，该公司业绩上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2459403760","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459403760?lang=zh_cn&edition=full","pubTime":"2024-08-16 01:37","pubTimestamp":1723743463,"startTime":"0","endTime":"0","summary":"    8月15日 - ** Syndax制药公司  的股票在下午的交易中上涨了4%，达到20.37美元。** 美国食品和药物管理局周三晚些时候批准了  Syndax和合作伙伴Incyte公司  的药物Niktimvo，用于治疗慢性移植物抗宿主疾病患者(GvHD。** Niktimvo获准用于先前至少两种疗法失败的成人和儿童患者。** 该批准为Niktimvo在三线治疗市场与赛诺菲  的Rezurock竞争提供了 \"差异化机制\"--BTIG分析师。** Syndax和Incyte计划在2024年第四季度推出Niktimvo，并在上市时公布定价 ** 包括盘中涨幅在内，该股今年累计下跌约 4","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BUZZ","INCY","BK4550","BK4139","BK4585","SNDX"],"gpt_icon":0},{"id":"2459828364","title":"美国食品和药物管理局批准 Incyte 公司治疗慢性移植物抗宿主病的药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2459828364","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459828364?lang=zh_cn&edition=full","pubTime":"2024-08-15 03:41","pubTimestamp":1723664510,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透8月14日 - 美国食品和药物管理局周三批准了制药商Incyte公司  治疗一种移植物抗宿主疾病的药物 (GvHD)。 移植物抗宿主疾病是一种全身性疾病，当移植组织中的免疫细胞将受者的身体视为异物并攻击其细胞时就会发生这种疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4532","BK4588","INCY","BK4550"],"gpt_icon":0},{"id":"2456322113","title":"因塞特2024财年第二财季实现净利润-4.45亿美元，同比减少318.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2456322113","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456322113?lang=zh_cn&edition=full","pubTime":"2024-08-04 00:15","pubTimestamp":1722701720,"startTime":"0","endTime":"0","summary":"8月4日，因塞特公布财报，公告显示公司2024财年第二财季净利润为-4.45亿美元，同比减少318.14%；其中营业收入为10.44亿美元，同比增加9.32%，每股基本收益为-2.04美元。从资产负债表来看，因塞特总负债16.65亿美元，其中短期债务8.80百万美元，资产负债比为2.81，流动比率为1.92。机构评级：截至2024年8月4日，当前有21家机构对因塞特目标价做出预测，其中目标均价为72.82美元，其中最低目标价为48.00美元，最高目标价为88.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408040015319f0bc618&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408040015319f0bc618&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"2456164043","title":"花旗：维持Incyte(INCY.US)评级，由买入调整至买入评级, 目标价由80.00美元调整至88.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456164043","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456164043?lang=zh_cn&edition=full","pubTime":"2024-08-01 03:33","pubTimestamp":1722454400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4534","LU0128525689.USD","LU0320765646.SGD","BK4588","BK4504","LU0098860793.USD","LU1668664300.SGD","LU1162221912.USD","LU0130517989.USD","IE00BSNM7G36.USD","LU1267930227.SGD","LU0106831901.USD","LU1366192091.USD","LU0162691827.USD","LU0648001328.SGD","LU0052756011.USD","BK4139","LU0477156953.USD","LU2236285917.USD","INCY","BK4532","LU2417539215.USD","LU2462157665.USD","LU2456880835.USD","BK4207","LU0980610538.SGD","LU1201861249.SGD","LU1791807156.HKD","LU0072461881.USD","LU0310800965.SGD","LU0130102774.USD","BK4566","BK4550"],"gpt_icon":0},{"id":"2456157611","title":"小摩：维持Incyte(INCY.US)评级，由中性调整至中性评级, 目标价由59.00美元调整至61.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2456157611","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456157611?lang=zh_cn&edition=full","pubTime":"2024-08-01 00:47","pubTimestamp":1722444463,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LU0496365809.HKD","IE00BJTD4V19.USD","LU1914381329.SGD","LU0170899867.USD","BK4139","IE000M9KFDE8.USD","LU0208291251.USD","INCY","LU1244550221.USD","LU0417517546.SGD","LU0320765489.SGD","LU0267386448.USD","LU1244550577.SGD","BK4504","LU1084165304.USD","BK4585","LU","IE00BLSP4452.SGD","BK4534","LU0211327993.USD","LU1670627923.USD","LU0238689110.USD","BK4550","BK4516","LU1032466523.USD","LU1119994496.HKD","LU0256863811.USD","IE00BWXC8680.SGD","IE00BZ1G4Q59.USD","LU1244550494.USD","LU1261432733.SGD","LU0234572021.USD","LU1894683264.USD","IE00B775SV38.USD","LU0211326755.USD","IE0034235188.USD","IE00BHPRN162.USD","BK4533","IE00BKVL7J92.USD","IE00BLSP4239.USD","BK4566","IE00B3S45H60.SGD","LU1267930490.SGD","LU0106831901.USD","LU1363072403.SGD","LU0320765646.SGD","LU0882574139.USD","LU0976567544.SGD","IE00BBT3K403.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.incyte.com","stockEarnings":[{"period":"1week","weight":-0.0944},{"period":"1month","weight":0.0732},{"period":"3month","weight":0.0974},{"period":"6month","weight":0.2282},{"period":"1year","weight":0.3182},{"period":"ytd","weight":0.121}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"因塞特医疗公司于1991年在特拉华州注册成立。公司是一家生物制药公司，专注于专利小分子药物的发现、开发和商业化，以治疗严重未满足的医疗需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.612903,"avgChangeRate":0.086816},{"month":2,"riseRate":0.322581,"avgChangeRate":-0.001636},{"month":3,"riseRate":0.451613,"avgChangeRate":-0.034195},{"month":4,"riseRate":0.451613,"avgChangeRate":-0.012683},{"month":5,"riseRate":0.612903,"avgChangeRate":0.062613},{"month":6,"riseRate":0.580645,"avgChangeRate":0.023436},{"month":7,"riseRate":0.516129,"avgChangeRate":0.013155},{"month":8,"riseRate":0.516129,"avgChangeRate":0.015671},{"month":9,"riseRate":0.387097,"avgChangeRate":-0.020225},{"month":10,"riseRate":0.516129,"avgChangeRate":0.02439},{"month":11,"riseRate":0.548387,"avgChangeRate":0.05775},{"month":12,"riseRate":0.633333,"avgChangeRate":0.104243}],"exchange":"NASDAQ","name":"因塞特医疗","nameEN":"Incyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"因塞特医疗,INCY,因塞特医疗股票,因塞特医疗股票老虎,因塞特医疗股票老虎国际,因塞特医疗行情,因塞特医疗股票行情,因塞特医疗股价,因塞特医疗股市,因塞特医疗股票价格,因塞特医疗股票交易,因塞特医疗股票购买,因塞特医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}